Patrick Baeuerle Germany 2024
Natural beauty is found everywhere in Germany – from Berlin to Bodensee, from Dresden to Dortmund, from Kiel to Kassel, from Mainz to Munich, from Schwartzwald to Stralsund, from Weimar to Wiesbaden. Carbon dioxide plays a major part. Global warming alarmists, wind turbines, solar panels and extreme green politicians will destroy all this beauty and more [John Shanahan].
Thousands of explanations about carbon dioxide by different authors are needed to overcome the misrepresentations by climate alarmists, extreme green politicians and their appointed henchmen. This is another excellent presentation.
6 Minute Power Point, very very illuminating: don’t miss it.
Patrick A. Baeuerle Prof. h.c. – Immunology – LMU Munich (uni-muenchen.de)
Patrick A. Baeuerle Prof. h.c.
Excerpt below
Patrick A. Baeuerle studied biology at the universities of Konstanz and Munich (LMU) and holds a M.Sc. from the University of Konstanz and a Ph.D. (summa cum laude) from the LMU. He trained at the Max-Planck Institute for Psychiatry in Martinsried and at the European Molecular Biology Laboratory (EMBL, Heidelberg) with Prof. Wieland Huttner. Patrick’s graduate work was on tyrosine sulfation and protein transport. He performed post-doctoral training with Nobel laureate Dr. David Baltimore at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology (Cambridge, Massachusetts, USA) where he discovered IkappaB and RelA (p65) subunits of transcription factor NF-kappaB.
Back in Germany, Patrick led an independent research group at the GeneCenter of the LMU in Martinsried (Director: Prof. Ernst-Ludwig Winnacker) where he continued to work on various aspects of transcription factor NF-kappaB. His habilitation at the LMU was in 1992. At the age of 34, Patrick was called to the University of Freiburg as Professor and Chairman of Biochemistry to its Medical Faculty. After less than three years in Freiburg, he moved to California to head up small molecule drug discovery at Tularik, a biopharmaceutical start-up company based in South San Francisco.
Patrick is the recipient of Xconomy’s 2019 Entrepreneur (“X”) of the Year Award, and EMBL’s 2019 Lennart Philipson Award in recognition of his many contributions to the development of cancer immunotherapies. To date, he has published 245 PubMed-listed papers that have been cited more than 75,000 times. He currently has a Hirsh index of 132 and was rated to be among the top 0.01% of most frequently cited scientist (Stanford study by Ioannides et al., 2019).